

(19)



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11)

**EP 1 049 787 B1**

(12)

**EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention  
of the grant of the patent:  
24.11.2004 Bulletin 2004/48

(21) Application number: 99907419.8

(22) Date of filing: 25.01.1999

(51) Int Cl.7: **C12N 15/62**, C07K 16/00,  
C07K 19/00, C07K 16/46,  
C12N 15/85, A61K 39/395,  
G01N 33/577  
// (C07K16/28, 16:40)

(86) International application number:  
PCT/EP1999/000477

(87) International publication number:  
WO 1999/037791 (29.07.1999 Gazette 1999/30)

(54) **MULTIPURPOSE ANTIBODY DERIVATIVES**  
MEHRZWECK-ANTIKÖRPERDERIVATE  
DERIVES D'ANTICORPS A USAGES MULTIPLES

(84) Designated Contracting States:  
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE

(30) Priority: 23.01.1998 EP 98200193

(43) Date of publication of application:  
08.11.2000 Bulletin 2000/45

(73) Proprietor: **Vlaams Interuniversitair Instituut voor  
Biotechnologie**  
9052 Zwijnaarde (BE)

(72) Inventors:  
• **SCHOONJANS, Reinhilde**  
B-0931 Drogen (BE)  
• **MERTENS, Nico**  
B-9120 Melsele (BE)  
• **FIERS, Walter**  
9070 Destelbergen (BE)  
• **CONTRERAS, Roland**  
9820 Schelderode-Merelbeke (BE)

(74) Representative: **De Clercq, Ann et al**  
**De Clercq, Brants & Partners c.v.,**  
Edgard Gevaertdreef 10a  
9830 Sint-Martens-Latem (BE)

(56) References cited:  
• **H. HOOGENBOOM**: "Mix and match: Building  
manifold binding sites." **NATURE**  
**BIOTECHNOLOGY**, vol. 15, no. 2, February 1997,  
pages 125-126, XP002084229 New York, NY, USA

- **H. FELL ET AL.**: "Genetic construction and characterization of a chieric F(ab') with specificity for carcinomas and human IL-2." **THE JOURNAL OF IMMUNOLOGY**, vol. 146, no. 7, 1 April 1991, pages 2446-2452, XP002084230 Baltimore, MD, USA
- **F. DUCANCEL ET AL.**: "Genetically engineered colorimetric antibody." **PROTEIN ENGINEERING**, vol. 6, no. suppl., 1993, page 87 XP002084231 Oxford, GB
- **E. NYSSÖNEN ET AL.**: "Efficient prouction of antibody fragments by the filamentous fungus *Trichoderma reesei*." **BIO/TECHNOLOGY**, vol. 11, no. 5, May 1993, pages 591-595, XP002084232 New York, NY, USA
- **M. NEDELMAN ET AL.**: "Rapid infarct imaging with a technetium-99m-labeled antimyosin recombinant single-chain Fv: Evaluation in a canine model of acute myocardial infarction." **THE JOURNAL OF NUCLEAR MEDICINE**, vol. 34, no. 2, February 1993, pages 234-241, XP002084233 New York, NY, USA
- **D. ANDERSON ET AL.**: "Enhanced in vitro tumor cell retention and internalization of antibody derivatized with synthetic peptides." **BIOCONJUGATE CHEMISTRY**, vol. 4, no. 1, January 1993, pages 10-18, XP002084234 Washington, DC, USA

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 1 049 787 B1**